Pfizer’s Plans To Market Accupril As A “Branded Generic” Challenged By Teva
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer intends to sell generic quinapril through its Greenstone subsidiary as soon as Teva triggers its own 180-day marketing exclusivity for the ACE inhibitor, Teva’s citizen petition to FDA states. Teva asserts Pfizer should be required to file a preapproval supplemental NDA before marketing the generic.
You may also be interested in...
Teva Accupril Generic Delayed Until 2007; Pfizer Patent Is Valid, Court Says
If upheld on appeal, the decision would eliminate Teva’s 180-day exclusivity period and make a challenge to Pfizer’s own generic moot. A New Jersey federal judge finds there was no inequitable conduct before the PTO regarding Pfizer’s patent for its ACE inhibitor.
Teva Accupril Generic Delayed Until 2007; Pfizer Patent Is Valid, Court Says
If upheld on appeal, the decision would eliminate Teva’s 180-day exclusivity period and make a challenge to Pfizer’s own generic moot. A New Jersey federal judge finds there was no inequitable conduct before the PTO regarding Pfizer’s patent for its ACE inhibitor.
P&G/Watson Macrobid "Authorized" Generic Launch Prompts Mylan Lawsuit
The practice of a branded company "authorizing" a generic misleads consumers and undercuts Waxman/Hatch incentives, Mylan says. Watson launched its generic one day after Mylan received ANDA approval and began marketing nitrofurantoin under 180 days of exclusivity.